Alkermes plc filings document a Nasdaq-listed Irish public limited biopharmaceutical company focused on neuroscience medicines. The record includes 8-K reports for operating results, financial expectations, investor presentations, material definitive agreements and Regulation FD disclosures, along with proxy materials for annual general meeting matters, director elections, executive compensation and shareholder voting.
Capital-structure disclosures cover ordinary shares listed under ALKS and senior secured term loan facilities used in connection with completed acquisition activity. Material-event reports also address governance and executive transition matters, compensatory arrangements, commercial-product performance and clinical-stage disclosures for the company’s orexin 2 receptor agonist programs.
Alkermes plc receipt of a Rule 144 notice indicates a proposed sale of 2,034 shares of common stock. The filing lists the issuer as Alkermes plc, the filer name David Gaffin, and a transaction date of 03/03/2026 on NASDAQ.
The filing also lists vesting entries for restricted stock unit and performance share unit awards dated 03/03/2017, 03/03/2018, 05/28/2015, and 10/05/2015, and notes a prior sale by the filer on 03/02/2026.
Alkermes plc submitted a Rule 144 notice reporting 6,000 shares of Common Stock to be sold with an aggregate price of $180,000.00; the filing lists beneficial ownership of 166,649,934 shares as of 03/02/2026. The filing also lists recent vesting of restricted stock units: 897 on 02/23/2025, 3,952 on 02/22/2025, and 1,151 on 02/18/2025.
Alkermes plc. (ALKS) officer David Gaffin reported a proposed sale of 2,034 common shares, with an aggregate market value of $59,575.86 and an approximate sale date of March 2, 2026. Merrill Lynch is named as broker. The reported date for plan adoption or giving instructions, in the field used when relying on Rule 10b5-1, is November 19, 2025. The listed acquisition records show 322 shares acquired through vesting of a restricted stock unit award on March 3, 2017, and 1,712 shares through award vesting on February 17, 2018.
Alkermes plc officer Craig Hopkinson gave notice of a proposed sale of 9,000 ordinary shares, with an aggregate market value of 267,485.14, for an approximate sale date of March 2, 2026. The notice lists March 14, 2025 as the adoption or instruction date for a Rule 10b5-1 plan. The shares comprise 5,000 acquired through exercise of employee stock options and 4,000 from vesting of a performance share award.
Alkermes plc vice president of finance Samuel Joseph Parisi reported equity transactions involving restricted stock units and ordinary shares. On February 26, 2026, he acquired 2,747 ordinary shares through the exercise/conversion of a restricted stock unit award, with each unit representing one ordinary share. Following this, a separate transaction disposed of 808 ordinary shares at $30.73 per share to cover tax obligations, leaving him with 14,607 ordinary shares held directly. The underlying restricted stock unit award vests in four equal annual installments beginning on February 26, 2025.
Alkermes plc SVP and Chief Commercial Officer Christian Todd Nichols reported equity award activity involving restricted stock units and ordinary shares. On 2026-02-26, he exercised 5,410 restricted stock units, which converted into 5,410 ordinary shares at a stated price of $0.0000 per share.
A related Form 4 line shows 2,403 ordinary shares disposed of at $30.73 per share in a code F transaction, which reflects shares withheld to satisfy tax obligations rather than an open-market sale. After these transactions, Nichols directly owned 115,769 ordinary shares and held 10,819 restricted stock units, each representing a contingent right to receive one ordinary share. The restricted stock unit award vests in four equal annual installments beginning on 02/26/2025.
Alkermes plc EVP and COO Jackson Blair Curtis reported equity compensation-related transactions. On February 26, 2026, he acquired 8,322 ordinary shares upon the exercise of a restricted stock unit award, with each unit representing one ordinary share. On the same date, 3,695 ordinary shares were disposed of at $30.73 per share to satisfy tax withholding obligations. Following these transactions, Curtis directly owned 241,308 ordinary shares. The underlying restricted stock units vest in four equal annual installments beginning on February 26, 2025.
Alkermes plc executive Craig C. Hopkinson reported equity award activity involving restricted stock units and ordinary shares. On 2/26/2026, he exercised 6,866 restricted stock units, which converted into 6,866 ordinary shares at a stated price of $0.0000 per share. In a related tax-withholding transaction, 3,049 ordinary shares were disposed of at $30.73 per share to cover tax obligations rather than as an open-market sale. Following these transactions, he directly held 93,389 ordinary shares and 13,732 restricted stock units. Each restricted stock unit represents a contingent right to receive one ordinary share and the award vests in four equal annual installments commencing on 02/26/2025.
Alkermes plc executive David Joseph Gaffin reported equity award activity. On 2/26/2026, he acquired 6,866 restricted stock units and 6,866 ordinary shares through an exercise or conversion of derivative securities. A separate transaction disposed of 3,049 ordinary shares at $30.73 per share to satisfy tax obligations.
After these transactions, Gaffin directly held 13,732 restricted stock units and 239,694 ordinary shares. Each restricted stock unit represents a contingent right to receive one ordinary share, and the award vests in four equal annual installments beginning on 2/26/2025.
Alkermes plc VP Samuel Joseph Parisi reported equity award activity. On 2/23/2026, 2,283 restricted stock units were exercised or converted into 2,283 ordinary shares at a price of $0.00 per share. A separate transaction disposed of 672 ordinary shares at $32.19 per share to cover tax withholding obligations. Each restricted stock unit represents a contingent right to receive one ordinary share, and the award vests in four equal annual installments starting on 2/23/2024. After these transactions, he directly held 2,284 restricted stock units and 12,668 ordinary shares.